Intervention not reported
Recurrence (loco‐regional) ‐ endocrine therapies not separated (exemestane (AI)/tamoxifen (SERM)) · women receiving endocrine therapy (selective oestrogen receptor modulator or aromatase inhibitor)
1 finding from 1 review
- Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review 2021 · Cochrane Headline outcomes onlyno estimate extracted1 study · 284 participantsVery low